08 Jun 2021 OXURION completes patient enrollment for Part A of Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME) Member news
02 Jun 2021 RheaVita closes EUR 2.5 million Series A Financing co-led by Novalis Biotech Acceleration and PMV Member news
More info? Ellen Telleir Communication Coordinator linkedin.com/in/ellentelleir/ +32 9 241 80 41 ellen.telleir@flanders.bio Contact us